What happened
GC Biopharma filed provisional (unaudited) consolidated results for Q2 2026: revenue of US$296M (−15.8% year on year), operating profit of US$1.2M (−93.8% year on year) and net income of US$774K (−96.6% year on year).
These are preliminary figures the company disclosed ahead of its audited report; the final numbers can differ.
| Revenue | US$296M |
|---|---|
| Revenue vs a year earlier | −15.8% |
| Operating profit | US$1.2M |
| Net income | US$774K |
| Period | Q2 2026 (consolidated) |
| Filed | 2026-07-31, Operating results (consolidated) (preliminary) (fair disclosure) |
| Source | DART rcept 20260731800768 → open original filing |
Source: DART. Information only, not investment advice.